Evidence map›Paper›PMID 39193166›Full record

ArticleWorld journal of clinical oncology2024

Implications of genetic testing and informed consent before and after genetic testing in individuals with cancer.

Priyanka Kumar, David J Benjamin, Sourat Darabi, Goetz Kloecker, Arash Rezazadeh Kalebasty

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Priyanka KumarDepartment of Hematology and Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, United States.
David J BenjaminDepartment of Medical Oncology, Hoag Family Cancer Institute, Newport Beach, CA 92663, United States. david.benjamin@hoag.org.
Sourat DarabiDepartment of Precision Medicine, Hoag Family Cancer Institute, Newport Beach, CA 92663, United States.
Goetz KloeckerDepartment of Hematology and Medical Oncology, University of Louisville, Louisville, KY 40202, United States.
Arash Rezazadeh KalebastyDepartment of Hematology and Medical Oncology, University of California-Irvine, Orange, CA 92868, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancements in next generation sequencing have allowed for genetic information become more readily available in the clinical setting for those affected by cancer and by treating clinicians. Given the lack of access to geneticists, medical oncologists and other treating physicians have begun ordering and interpreting genetic tests for individuals with cancer through the process of "mainstreaming". While this process has allowed for quicker access to genetic tests, the process of "mainstreaming" has also brought several challenges including the dissemination of variants of unknown significance results, ordering of appropriate tests, and accurate interpretation of genetic results with appropriate follow-up testing and interventions. In this editorial, we seek to explore the process of informed consent of individuals before obtaining genetic testing and offer potential solutions to optimize the informed consent process including categorization of results as well as a layered consent model.

Indexed as

Genetic counselingGenetic testingInformed consentLayered consentMainstreamingNext generation sequencing

Identifiers

PMID39193166
PMCPMC11346064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.